https://vbiva.wpengine.com/2023-03-13daily0.8https://vbiva.wpengine.com/investors/events-and-presentations/2023-03-13daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-to-discuss-progress-in-hepatitis-b-portfolio-in-analyst-led-fireside-chat/2023-03-13daily0.8https://vbiva.wpengine.com/press-releases/interim-phase-2-data-evaluating-combination-of-vbi-2601-and-brii-835/2023-03-13daily0.8https://vbiva.wpengine.com/press-releases/2022-results/2023-03-13daily0.8https://vbiva.wpengine.com/about/management-team/2023-03-13daily0.8https://vbiva.wpengine.com/about/board-of-directors/2023-03-13daily0.8https://vbiva.wpengine.com/our-pipeline/clinical-trials/2023-03-12daily0.8https://vbiva.wpengine.com/news-and-resources/2023-03-07daily0.8https://vbiva.wpengine.com/our-focus/2023-03-07daily0.8https://vbiva.wpengine.com/our-pipeline/expanded-access/2023-03-07daily0.8https://vbiva.wpengine.com/our-pipeline/2023-03-07daily0.8https://vbiva.wpengine.com/document-library/2023-03-07daily0.8https://vbiva.wpengine.com/prehevbrio/2023-03-07daily0.8https://vbiva.wpengine.com/conferences/gbm-program-update-sno-2018/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/late-breaking-poster-presentation-at-easl-2019/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/vbi-1901-study-data-recurrent-gbm-asco-2019/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/the-liver-meeting-2019-late-breaker/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/gbm-tumor-response-data-sno-2019/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/aacr-june-2020/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/easl-2020-presentations/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/esmo-2020-poster/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/id-week-2020/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/scibvac-liver-meeting-2020/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/sno-2020-phase-2a-data/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/liver-meeting-2021/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/vbi-1901-gbm-fda-fast-track-designation/2023-03-06daily0.8https://vbiva.wpengine.com/conferences/upcoming-scientific-conferences-2021/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-e-poster-presentation-of-3-antigen-prophylactic-hepatitis-b-vaccine-data-at-the-liver-meeting-2021/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/gbm-asco-2022/2023-03-06daily0.8https://vbiva.wpengine.com/press-releases/vbi-1901-phase-1-2a-data-sno-2022/2023-03-03daily0.8https://vbiva.wpengine.com/investors/corporate-governance/2023-03-03daily0.8https://vbiva.wpengine.com/investors/press-releases/2023-03-03daily0.8https://vbiva.wpengine.com/privacy-policy/2023-03-02daily0.8https://vbiva.wpengine.com/cookies-policy/2023-03-02daily0.8https://vbiva.wpengine.com/terms-of-use/2023-03-02daily0.8https://vbiva.wpengine.com/news-and-resources/videos/2023-03-01daily0.8https://vbiva.wpengine.com/news-and-resources/posters/2023-03-01daily0.8https://vbiva.wpengine.com/news-and-resources/publications/2023-02-28daily0.8https://vbiva.wpengine.com/investors/stock-information/2023-02-28daily0.8https://vbiva.wpengine.com/investors/filings/2023-02-28daily0.8https://vbiva.wpengine.com/press-releases/health-canada-approval-for-prehevbrio/2023-02-28daily0.8https://vbiva.wpengine.com/investors/2023-02-28daily0.8https://vbiva.wpengine.com/investors/company-information/2023-02-28daily0.8https://vbiva.wpengine.com/about/2023-02-27daily0.8https://vbiva.wpengine.com/about/scientific-and-clinical-advisory-boards/2023-02-26daily0.8https://vbiva.wpengine.com/about/commercial-advisory-board/2023-02-26daily0.8https://vbiva.wpengine.com/contact/2023-02-25daily0.8https://vbiva.wpengine.com/careers/2023-02-25daily0.8https://vbiva.wpengine.com/partnerships/2023-02-25daily0.8https://vbiva.wpengine.com/site-map/2023-02-24daily0.8https://vbiva.wpengine.com/our-science-and-technology/2023-02-24daily0.8https://vbiva.wpengine.com/report-an-adverse-event/2023-02-21daily0.8https://vbiva.wpengine.com/subscribe/2023-02-21daily0.8https://vbiva.wpengine.com/press-releases/cepi-boosts-coronavirus-x-vaccine-search-with-expanded-vbi-vaccines-deal/2022-12-06daily0.8https://vbiva.wpengine.com/press-releases/november-2022-investor-conferences/2022-11-11daily0.8https://vbiva.wpengine.com/press-releases/sno-2022/2022-11-10daily0.8https://vbiva.wpengine.com/press-releases/q3-2022/2022-11-09daily0.8https://vbiva.wpengine.com/conferences/hcw-hbv-conference-2022/2022-10-14daily0.8https://vbiva.wpengine.com/press-releases/agenus-collaboration/2022-10-14daily0.8https://vbiva.wpengine.com/press-releases/initiation-phase-1-study-multivalent-coronavirus/2022-09-28daily0.8https://vbiva.wpengine.com/press-releases/uk-mhra-marketing-authorisation-for-prehevbri/2022-09-27daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-presentation-of-physician-initiated-compassionate-use-data-of-its-3-antigen-hepatitis-b-vaccine-at-the-2022-international-hbv-meeting/2022-09-20daily0.8https://vbiva.wpengine.com/press-releases/100-million-debt-facility-k2-healthventures/2022-09-15daily0.8https://vbiva.wpengine.com/press-releases/valneva-partnership/2022-09-07daily0.8https://vbiva.wpengine.com/press-releases/q2-2022/2022-08-07daily0.8https://vbiva.wpengine.com/press-releases/john-dillman-chief-commercial-officer/2022-07-11daily0.8https://vbiva.wpengine.com/press-releases/hepatitis-b-easl-2022/2022-06-27daily0.8https://vbiva.wpengine.com/press-releases/agm-2022/2022-06-22daily0.8https://vbiva.wpengine.com/press-releases/fda-orphan-drug-designation-vbi-1901-gbm/2022-06-21daily0.8https://vbiva.wpengine.com/conferences/jefferies-2022/2022-06-06daily0.8https://vbiva.wpengine.com/press-releases/ispor-2022/2022-05-27daily0.8https://vbiva.wpengine.com/conferences/easl-2022/2022-05-25daily0.8https://vbiva.wpengine.com/press-releases/q1-2022/2022-05-07daily0.8https://vbiva.wpengine.com/press-releases/european-commission-marketing-authorisation-for-prehevbri/2022-05-02daily0.8https://vbiva.wpengine.com/conferences/asco-2022/2022-04-27daily0.8https://vbiva.wpengine.com/press-releases/new-data-and-progress-of-vbi-2900-coronavirus-program/2022-04-04daily0.8https://vbiva.wpengine.com/press-releases/prehevbrio-available/2022-03-29daily0.8https://vbiva.wpengine.com/conferences/oppenheimer-2022/2022-03-14daily0.8https://vbiva.wpengine.com/press-releases/2021-results/2022-03-09daily0.8https://vbiva.wpengine.com/press-releases/positive-chmp-opinion-for-3-antigen-hepatitis-b-vaccine-for-immunization-against-hepatitis-b-infection-in-adults-in-the-eu/2022-02-25daily0.8https://vbiva.wpengine.com/press-releases/prehevbrio-recommended-cdc-acip-for-the-prevention-of-hepatitis-b/2022-02-23daily0.8https://vbiva.wpengine.com/conferences/b-riley-2022/2022-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-dosing-of-first-patient-in-second-phase-2-study-in-chronic-hepatitis-b-patients-as-part-of-expansion-of-clinical-collaboration-with-brii-bio/2022-01-04daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-filing-of-new-drug-submission-for-3-antigen-hepatitis-b-vaccine-to-health-canada/2021-12-08daily0.8https://vbiva.wpengine.com/press-releases/world-vaccine-immunotherapy-congress-2021/2021-12-01daily0.8https://vbiva.wpengine.com/press-releases/prehevbrio-approval/2021-12-01daily0.8https://vbiva.wpengine.com/press-releases/jefferies-london-2021/2021-11-15daily0.8https://vbiva.wpengine.com/press-releases/q3-2021-results/2021-11-05daily0.8https://vbiva.wpengine.com/press-releases/publication-of-constant-results-in-jama/2021-10-12daily0.8https://vbiva.wpengine.com/press-releases/october-conferences/2021-10-01daily0.8https://vbiva.wpengine.com/press-releases/initiation-of-vbi-2905-clinical-study/2021-09-30daily0.8https://vbiva.wpengine.com/press-releases/q2-2021/2021-07-29daily0.8https://vbiva.wpengine.com/press-releases/linda-bain/2021-07-06daily0.8https://vbiva.wpengine.com/press-releases/new-cpt-code/2021-07-01daily0.8https://vbiva.wpengine.com/press-releases/covid-19-vaccine-phase-1-data/2021-06-28daily0.8https://vbiva.wpengine.com/conferences/international-liver-congress-2021/2021-06-23daily0.8https://vbiva.wpengine.com/video/enveloped-virus-like-particle-evlp-platform-technology/2021-06-15daily0.8https://vbiva.wpengine.com/video/cytomegalovirus-cmv-vaccine-candidate/2021-06-15daily0.8https://vbiva.wpengine.com/video/about-hepatitis-b/2021-06-15daily0.8https://vbiva.wpengine.com/video/about-glioblastoma-gbm/2021-06-15daily0.8https://vbiva.wpengine.com/video/about-medulloblastoma-mb/2021-06-15daily0.8https://vbiva.wpengine.com/video/preclinical-studies-in-glioblastoma-gbm/2021-06-15daily0.8https://vbiva.wpengine.com/video/vbi-1901-therapeutic-cancer-vaccine-design/2021-06-15daily0.8https://vbiva.wpengine.com/video/first-and-second-generation-hepatitis-b-vaccines/2021-06-15daily0.8https://vbiva.wpengine.com/video/vbi-1901-sno-2020-update/2021-06-15daily0.8https://vbiva.wpengine.com/video/aacr-2020-video/2021-06-15daily0.8https://vbiva.wpengine.com/press-releases/agm-results-2021/2021-06-09daily0.8https://vbiva.wpengine.com/conferences/easl-2021/2021-06-08daily0.8https://vbiva.wpengine.com/conferences/keystone-2016/2021-05-31daily0.8https://vbiva.wpengine.com/conferences/upcoming-conferences-may-2021/2021-05-28daily0.8https://vbiva.wpengine.com/press-releases/may-2021-debt-financing/2021-05-21daily0.8https://vbiva.wpengine.com/conferences/asco-2021/2021-05-19daily0.8https://vbiva.wpengine.com/press-releases/lancet-protect-phase-3-results/2021-05-12daily0.8https://vbiva.wpengine.com/press-releases/q1-2021/2021-05-08daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-second-phase-3-study/2021-05-04daily0.8https://vbiva.wpengine.com/press-releases/q1-2020-results-and-corporate-update/2021-05-04daily0.8https://vbiva.wpengine.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/2021-04-30daily0.8https://vbiva.wpengine.com/press-releases/2019-results-and-corporate-update/2021-04-30daily0.8https://vbiva.wpengine.com/conferences/investor-conferences-june-2020/2021-04-29daily0.8https://vbiva.wpengine.com/press-releases/results-of-2020-agm/2021-04-29daily0.8https://vbiva.wpengine.com/press-releases/canadian-govt-coronavirus-award/2021-04-27daily0.8https://vbiva.wpengine.com/press-releases/easl-2020/2021-04-27daily0.8https://vbiva.wpengine.com/press-releases/preclinical-coronavirus-data-candidate-selection/2021-04-27daily0.8https://vbiva.wpengine.com/conferences/wvc-and-id-week-2020/2021-04-27daily0.8https://vbiva.wpengine.com/conferences/the-liver-meeting-2020/2021-04-27daily0.8https://vbiva.wpengine.com/conferences/h-c-wainwright-hbv-2020/2021-04-27daily0.8https://vbiva.wpengine.com/press-releases/q3-2020-results-and-corporate-update/2021-04-27daily0.8https://vbiva.wpengine.com/conferences/sno-2020/2021-04-27daily0.8https://vbiva.wpengine.com/press-releases/interim-phase-1b-2a-data-for-hepatitis-b/2021-04-27daily0.8https://vbiva.wpengine.com/press-releases/national-securities-corporation-biotech-investor-summit-2021/2021-04-26daily0.8https://vbiva.wpengine.com/press-releases/2021-annual-conference-on-vaccinology-research/2021-04-26daily0.8https://vbiva.wpengine.com/press-releases/brii-vir-vbi-phase-2-hepatitis-b-combination-study/2021-04-21daily0.8https://vbiva.wpengine.com/press-releases/hepatitis-b-immunotherapy-phase-1b-2a-data/2021-04-11daily0.8https://vbiva.wpengine.com/conferences/oppenheimer-2021/2021-03-31daily0.8https://vbiva.wpengine.com/sci-b-vac/the-rationale-for-developing-a-more-immunogenic-hepatitis-b-vaccine/2021-03-24daily0.8https://vbiva.wpengine.com/press-releases/enrollment-in-phase-1-2-covid-study/2021-03-09daily0.8https://vbiva.wpengine.com/press-releases/cepi-collaboration/2021-03-09daily0.8https://vbiva.wpengine.com/press-releases/vbi-gsk-research-collaboration/2021-03-01daily0.8https://vbiva.wpengine.com/press-releases/q4-and-2020-results/2021-03-01daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-to-present-at-the-raymond-james-42nd-annual-institutional-investors-conference/2021-02-27daily0.8https://vbiva.wpengine.com/press-releases/q2-2020-results-and-corporate-update/2021-02-25daily0.8https://vbiva.wpengine.com/press-releases/results-of-phase-4-hepatitis-b-study/2021-02-18daily0.8https://vbiva.wpengine.com/publication/enhanced-immune-response-to-hepatitis-b-vaccination-through-immunization-with-a-pre-s1-pre-s2-s-vaccine/2021-02-18daily0.8https://vbiva.wpengine.com/conferences/esmo-2020/2021-02-15daily0.8https://vbiva.wpengine.com/publication/rapid-and-high-seroprotection-rates-achieved-with-a-tri-antigenic-hepatitis-b-vaccine-in-healthy-young-adults-results-from-a-phase-iv-study/2021-02-13daily0.8https://vbiva.wpengine.com/conferences/raymond-james-2020/2021-02-09daily0.8https://vbiva.wpengine.com/publication/tetanus-toxoid-and-ccl3-improve-dendritic-cell-vaccines-in-mice-and-glioblastoma-patients/2021-02-09daily0.8https://vbiva.wpengine.com/publication/long-term-survival-in-glioblastoma-with-cytomegalovirus-pp65-targeted-vaccination/2021-02-09daily0.8https://vbiva.wpengine.com/publication/enveloped-virus-like-particle-expression-of-human-cytomegalovirus-glycoprotein-b-antigen-induces-antibodies-with-potent-and-broad-neutralizing-activity/2021-02-09daily0.8https://vbiva.wpengine.com/publication/randomized-controlled-study-investigating-viral-suppression-and-serological-response-following-pre-s1-pre-s2-s-vaccine-therapy-combined-with-lamivudine-treatment-in-hbeag-positive-patients-with-chroni/2021-02-09daily0.8https://vbiva.wpengine.com/publication/three-decades-of-hepatitis-b-control-with-vaccination/2021-02-09daily0.8https://vbiva.wpengine.com/publication/autologous-t-cell-therapy-for-cytomegalovirus-as-a-consolidative-treatment-for-recurrent-glioblastoma/2021-02-09daily0.8https://vbiva.wpengine.com/publication/recognition-and-killing-of-autologous-primary-glioblastoma-tumor-cells-by-human-cytomegalovirus-pp65-specific-cytotoxic-t-cells/2021-02-09daily0.8https://vbiva.wpengine.com/archived-press-releases/vbi-announces-acquisition-of-epixis-and-its-innovative-evlp-vaccine-platform/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-vaccine-design-preclinical-data/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/houston-congenital-cmv-study-spans-32-years/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/paulson-capital-and-vbi-enter-into-merger-agreement/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/vbi-and-paulson-capital-announce-completion-of-merger/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/new-cmv-data-presented-at-icaac/2021-02-03daily0.8https://vbiva.wpengine.com/thermostable-platform/thermostable-vaccines-overview-and-market-opportunity/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/vbi-to-present-at-the-cmv-public-health-policy-conference/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/q3-2014-results/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/ld-micro-conference/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/small-cap-stars-conference/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/vbi-at-noble-financial-2015/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/le-classique-cmv-canada/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/jeff-baxter-equities-interview/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/vbi-partners-with-the-utah-cmv-council/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cdc-evaluates-cmv-education-materials/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/sanofi-pasteur-collaboration/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-vaccine-update-wvc-2015/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/mvads-2015/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/wvc-asia-2015/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/bio-2015/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/private-placement-august-2015/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/imvacs-2015/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/rodman-2015/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/rsv-funding/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/dr-david-anderson-chief-scientific-officer/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/biotech-in-europe-forum-2015/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/gbm-immunotherapy-candidate/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/vbi-scivac-merger-agreement/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/merger-conference-call/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/merger-webcast/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/wvce-2015/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/esmo-2015/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/ld-mirco-2015/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/noblecon-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/bioceo-2016/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/le-classique-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/roth-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/wvc-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/f4-registration-effective/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/bloom-burton-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/scivac-merger/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/scivac-merger-details/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/jefferies-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/bio-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/hbv-kol-meeting/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/medulloblastoma-immunotherapy-candidate/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/vlpnpv-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/private-placement-2016/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-program-phase-1-trial/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/nasdaq-opening-bell/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/zika-vaccine-candidate/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/diaz-mitoma-cmo/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-study-dsmb-review/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/io-summit/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/tenth-vaccine-congress/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/rodman-2016/2021-02-03daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-phase-1-enrollment-complete/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/ladenburg-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/results-of-meeting-2016/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/wvc-europe-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/pre-ind-meeting-gbm-candidate/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/keystone-2016-london/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/sno-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-phase-iv-interim-results/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/imvacs-2016/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/23-million-financing/2021-02-03daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-phase-3-study-ema-advice/2021-02-03daily0.8https://vbiva.wpengine.com/conferences/conference-call-to-review-sci-b-vac-protect-phase-3-clinical-data/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q2-2018-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/2018-oppenheimer-boston-oncology-insight-summit/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/jpm-2018/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/2018-annual-general-meeting-results/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-vaccine-phase-1-study-results/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q1-2018-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-protect-phase-3-enrollment-complete/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/positive-dsmb-review-in-phase-1-2a-gbm-study/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/changes-to-board-of-directors/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/gbm-phase-1-2-a-study/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-phase-3-initiation/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/bmo-2017/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/sitc-2017/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-appoints-ran-nussbaum-to-bod/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/oct-2017-offering-closing/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/oct-2017-offering-upsized/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/oct-2017-offering-pricing/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/oct-2017-offering/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/aasld-2017/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/wvc-europe-2017/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/september-2017-investor-events/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-phase-3-fda-ind/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/io-summit-2017/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/gbm-program-fda-ind/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-vaccine-interim-phase-1-study-data/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/voluntary-delisting-from-tsx/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-phase-i-clinical-study-update-may-2017/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/jefferies-2017/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-fda-pre-ind-meeting/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-added-to-russell-indexes/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/annual-general-and-special-meeting-2017/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/sci-b-vac-phase-3-clinical-program/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/wvc-2017/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/avi-mazaltov-appointed-global-head-of-manufacturing/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/sci-b-vac-phase-3-study-health-canada-evaluation/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/canaccord-genuity-2018/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/christopher-mcnulty-appointed-cfo-head-of-bd/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/rodman-renshaw-2018/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/unfounded-allegations-in-globes-article/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/second-dsmb-review-gbm-immunotherapy/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/formation-of-new-scientific-and-clinical-advisory-boards/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/fda-bla-filing-hep-b-vaccine/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/coronavirus-vaccine-program-update/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/ladenburg-thalmann-2018/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-presentation-idweek-2018/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vaccination-in-protect-phase-3-clinical-study-for-sci-b-vac-hepatitis-b-vaccine-complete/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q3-2018-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-agreement-with-brii-bio-to-develop-functional-cure-for-hbv/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/proposed-public-offering-of-common-shares-dec-2018/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/pricing-of-dec-2018-offering/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/close-of-dec-2018-offering/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-vaccines-phase-2-design/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-appoints-blaine-mckee-to-bod/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/third-positive-dsmb-review-in-phase-1-2a-study-in-recurrent-gbm/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/2018-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/oppenheimer-2019/2021-02-02daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/poster-presentation-7th-international-congenital-cmv-conference-17th-international-cmv-workshop/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-appoints-joanne-cordeiro-to-board-of-directors/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-appoints-dr-vlad-popovic-as-vice-president-of-clinical-development-and-medical-affairs/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/update-on-gbm-program-april-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q1-2019-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-results-of-annual-general-meeting/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-positive-top-line-results-from-protect-a-pivotal-phase-3-study-of-sci-b-vac/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/bmo-capital-markets-conference-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-added-to-russell-2000-and-russell-3000-indexes/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/dosing-of-first-recurrent-gbm-patient-in-part-b-of-ongoing-phase-1-2a-study-of-vbi-1901/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/canaccord-genuity-39th-annual-growth-conference/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q2-2019-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/hc-wainwright-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/gsk-gbm-collaboration/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/public-offering-sept-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/pricing-of-35-million-public-offering/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/closing-of-sept-2019-offering/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/idweek-2019-late-breaker-presentation/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/wvce-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/q3-2019-results-and-corporate-update/2021-02-02daily0.8https://vbiva.wpengine.com/conferences/gbm-part-b-data-sno-2019/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-and-brii-initiate-phase-1b-2a-study-of-brii-179-in-chronic-hbv/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/vbi-regains-compliance-with-nasdaq-minimum-bid-price-requirement/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/dosing-of-first-gbm-patient-in-gsk-phase-2a-comb-study/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/gbm-gsk-phase1-2a-study-update/2021-02-02daily0.8https://vbiva.wpengine.com/press-releases/damian-braga-board-of-directors/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/nrc-pan-coronavirus-vaccine-collaboration/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/proposed-offering-april-2020/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/offering-pricing-april-2020/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/offering-closing-april-2020/2021-02-01daily0.8https://vbiva.wpengine.com/conferences/aacr-2020/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/50-million-debt-financing-2020/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/formation-of-commercial-advisory-board/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/hepatitis-b-vaccine-fda-bla-submission/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/hepatitis-b-vaccine-naa-ema-submission/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/syneos-health-commercialization-partner/2021-02-01daily0.8https://vbiva.wpengine.com/press-releases/vbi-vaccines-announces-european-medicines-agency-acceptance-of-marketing-authorization-application-maa-for-3-antigen-prophylactic-hepatitis-b-vaccine/2021-02-01daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-conference-utah/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/vbi-begins-gmp-tech-transfer-to-paragon-bioservices/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/dr-michael-cannon-cdc-webinar/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-awareness-lags-prevalence/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/icaac-presentation/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/utah-leads-the-u-s-in-cmv-screening-and-education/2021-01-17daily0.8https://vbiva.wpengine.com/conferences/vbi-to-present-at-the-sachs-associates-biotech-in-europe-forum/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-gbm-research/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/universal-cmv-screening-of-newborns-faces-systemic-challenges/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-immune-system-aging/2021-01-17daily0.8https://vbiva.wpengine.com/conferences/vbi-at-bio-europe/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-organ-transplant-market-overview/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/congenital-cmv-101/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/breast-milk-as-postnatal-cmv-transmission-source-in-vlbw-infants/2021-01-17daily0.8https://vbiva.wpengine.com/conferences/ld-micro-webcast/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/menafrivac-thermostable-vaccine/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-atherosclerosis-research/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/vaccine-cold-storage-guidelines/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-shedding-in-healthy-cmv-positive-children/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-gbm-new-research/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-twin-study/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/china-cold-chain/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/cold-chain-measles-potency/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/hawaii-cmv-legislation/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-prevention-strategies-video/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/postnatal-cmv-infection-in-premature-infants/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/heat-degradation-blamed-for-reduced-h1n1-vaccine-potency/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-and-fetal-development/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-legislation-2015/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/rabies-vaccine-cold-chain-failure/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/ct-cmv-law/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/freezing-cold-chain/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/three-states-enact-cmv-legislation-in-2015/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-charities/2021-01-17daily0.8https://vbiva.wpengine.com/respiratory-syncytial-virus-rsv/rsv-infection-in-infants-and-young-children/2021-01-17daily0.8https://vbiva.wpengine.com/respiratory-syncytial-virus-rsv/rsv-infection-in-elderly-and-high-risk-adults/2021-01-17daily0.8https://vbiva.wpengine.com/thermostable-platform/south-sudan-cold-chain/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-and-vestibular-disorders/2021-01-17daily0.8https://vbiva.wpengine.com/glioblastoma-gbm/cmv-antigens-gbm-immunotherapy/2021-01-17daily0.8https://vbiva.wpengine.com/evlp-platform/edward-jenner-and-the-first-modern-vaccine/2021-01-17daily0.8https://vbiva.wpengine.com/glioblastoma-gbm/neoantigens-in-cancer-immunotherapies/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-and-breast-cancer/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/iowa-cmv-legislation/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-infection-fetal-brain-development/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-and-alzheimers-disease/2021-01-17daily0.8https://vbiva.wpengine.com/zika/zika-background-history/2021-01-17daily0.8https://vbiva.wpengine.com/glioblastoma-gbm/cmv-memory-inflation/2021-01-17daily0.8https://vbiva.wpengine.com/evlp-platform/louis-pasteur-attenuated-vaccine/2021-01-17daily0.8https://vbiva.wpengine.com/sci-b-vac/elderly-hbv-infection/2021-01-17daily0.8https://vbiva.wpengine.com/zika/zika-virus-2017/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-all-link/2021-01-17daily0.8https://vbiva.wpengine.com/sci-b-vac/diabetes-hbv-infection/2021-01-17daily0.8https://vbiva.wpengine.com/sci-b-vac/esrd-hbv-infection/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/utah-cmv-legislation-outcomes/2021-01-17daily0.8https://vbiva.wpengine.com/sci-b-vac/healthcare-workers-hbv-infection/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-obesity-metabolic-syndrome/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/cmv-legislation-2017/2021-01-17daily0.8https://vbiva.wpengine.com/media-mentions/with-eyes-on-glaxos-engerix-b-vaccine-vbi-takes-hep-b-candidate-into-phase-3-via-fierce-vaccines/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/developing-vaccine-to-prevent-birth-defects-from-cytomegalovirus-empowered-patient-podcast/2021-01-17daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/virus-like-particle-vaccine-history-video/2014-08-05daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/vbis-evlp-based-cmv-vaccine-published-in-clinical-and-vaccine-immunology/2013-12-01daily0.8https://vbiva.wpengine.com/media-mentions/variation-bio-garners-250k-new-funding/2013-09-12daily0.8https://vbiva.wpengine.com/media-mentions/vbi-vaccines-pulls-in-2-2m-debt-round/2012-02-13daily0.8https://vbiva.wpengine.com/media-mentions/vbi-acquires-epixis-for-vlp-vaccines-capabilities/2011-09-15daily0.8https://vbiva.wpengine.com/cytomegalovirus-cmv/vbi-buys-epixis-gains-cmv-hep-c-vaccines/2011-09-15daily0.8https://vbiva.wpengine.com/media-mentions/variation-biotech-taps-backers-for-7-8m-in-debt-funding/2011-07-19daily0.8https://vbiva.wpengine.com/media-mentions/vbi-progressing-with-vaccines-that-dont-require-refrigeration/2011-03-24daily0.8https://vbiva.wpengine.com/press-releases/variation-biotechnologies-names-jeff-baxter-ceo/2009-09-22daily0.8https://vbiva.wpengine.com/archived-press-releases/variation-biotechnologies-secures-us-35-7-million-in-series-a-financing-to-fund-innovative-vaccine-platform/2007-01-04daily0.8